• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    8/19/22 2:27:29 PM ET
    $AGLE
    $APDN
    $AXDX
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Consumer Discretionary
    Get the next $AGLE alert in real time by email

     

    Gainers

    • Aeglea BioTherapeutics (NASDAQ:AGLE) stock increased by 64.8% to $0.83 during Friday's regular session. As of 13:30 EST, this security is trading at a volume of 60.0 million shares, making up 6897.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $50.9 million.
    • Axsome Therapeutics (NASDAQ:AXSM) stock increased by 33.53% to $56.66. As of 13:30 EST, Axsome Therapeutics's stock is trading at a volume of 19.0 million, which is 1413.6% of its average full-day volume over the last 100 days. The company's market cap stands at $2.2 billion.
    • Endo International (NASDAQ:ENDP) shares moved upwards by 18.16% to $0.48. Endo International's stock is trading at a volume of 192.0 million shares as of 13:30 EST. This is 330.3% of its average full-day volume over the last 100 days. The company's market cap stands at $112.7 million.
    • Applied DNA Sciences (NASDAQ:APDN) stock moved upwards by 14.72% to $4.13. Trading volume for this security as of 13:30 EST is 16.5 million, which is 243.2% of its average full-day volume over the last 100 days. The company's market cap stands at $53.2 million.
    • Summit Therapeutics (NASDAQ:SMMT) shares moved upwards by 12.99% to $1.13. Trading volume for Summit Therapeutics's stock is 11.5 million as of 13:30 EST. This is 5577.2% of its average full-day volume over the last 100 days. The company's market cap stands at $227.1 million.
    • Histogen (NASDAQ:HSTO) shares moved upwards by 9.55% to $2.06. Trading volume for Histogen's stock is 6.9 million as of 13:30 EST. This is 800.8% of its average full-day volume over the last 100 days. The company's market cap stands at $5.1 million.

    Losers

    • Accelerate Diagnostics (NASDAQ:AXDX) stock fell 35.5% to $1.6 during Friday's regular session. Trading volume for this security as of 13:30 EST is 8.4 million, which is 750.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $130.9 million. As per the news, the Q2 earnings report came out 4 days ago.
    • 23andMe Holding (NASDAQ:ME) stock fell 20.46% to $3.33. 23andMe Holding's stock is trading at a volume of 5.0 million shares as of 13:30 EST. This is 118.0% of its average full-day volume over the last 100 days. The company's market cap stands at $1.5 billion.
    • Nautilus Biotechnology (NASDAQ:NAUT) shares decreased by 16.48% to $2.23. As of 13:30 EST, this security is trading at a volume of 1.1 million shares, making up 317.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $277.9 million.
    • PAVmed (NASDAQ:PAVM) shares fell 15.6% to $1.22. Trading volume for PAVmed's stock is 1.0 million as of 13:30 EST. This is 80.2% of its average full-day volume over the last 100 days. The company's market cap stands at $110.6 million. As per the news, the Q2 earnings report came out 3 days ago.
    • Inotiv (NASDAQ:NOTV) shares fell 15.46% to $20.89. As of 13:30 EST, Inotiv's stock is trading at a volume of 300.4K, which is 135.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $534.6 million.
    • Phathom Pharmaceuticals (NASDAQ:PHAT) stock decreased by 14.29% to $10.38. Trading volume for this security as of 13:30 EST is 69.7K, which is 25.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $406.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGLE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGLE
    $APDN
    $AXDX
    $AXSM

    CompanyDatePrice TargetRatingAnalyst
    Axsome Therapeutics Inc.
    $AXSM
    2/24/2026$230.00Outperform
    Wolfe Research
    Axsome Therapeutics Inc.
    $AXSM
    1/8/2026$204.00Overweight → Equal-Weight
    Morgan Stanley
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Phathom Pharmaceuticals Inc.
    $PHAT
    12/12/2025$28.00Strong Buy
    Raymond James
    Phathom Pharmaceuticals Inc.
    $PHAT
    12/9/2025$16.00Equal Weight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    Axsome Therapeutics Inc.
    $AXSM
    10/1/2025$179.00Buy
    B. Riley Securities
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    More analyst ratings

    $AGLE
    $APDN
    $AXDX
    $AXSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, President, and Secretary Patel Sujal M bought $65,238 worth of shares (25,000 units at $2.61), increasing direct ownership by 0.24% to 10,366,721 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/4/26 6:37:20 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Marketing Officer Suzuki Kentaro bought $5,960 worth of shares (4,000 units at $1.49) (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    11/10/25 9:29:14 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Xia Yu bought $9,999,983 worth of shares (533,617 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 9:06:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $APDN
    $AXDX
    $AXSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight

    The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based therapies, and novel emerging therapies such as Rifasutenizol (TenNor Therapeutics), Linaprazan glurate (Cinclus Pharma), Tegoprazan (RQ-00000004) (RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals), and others, driven by improved eradication rates and safety profiles.LAS VEGAS, March 4, 2026 /PRNewswire/ -- Recently published H. pylori Infections Market Insights report includes a comprehensive understanding of current treatment practices, H. pylori infections emerging drugs, market share of individual therapies

    3/4/26 5:46:00 PM ET
    $CPIX
    $PHAT
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales

    SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering single-molecule proteome analysis, today announced the appointment of Amber Faust as Vice President of Sales. Ms. Faust joins Nautilus following the public debut of the Nautilus Voyager™ Platform, designed to deliver and scale Iterative Mapping, a method that enables single-molecule analysis of proteins and proteoforms across the proteome. Ms. Faust brings nearly two decades of commercial leadership experience in life sciences, with a focus on advancing adoption of emerging proteomics technologies across pharmaceutical, biotechnology, academic, clinical, and government sectors. S

    3/2/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Summit Therapeutics to Present at Upcoming Investor Conferences

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday, March 10, 2026 Investor meetings only Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026 Fireside chat 2:15pm ET The fireside chats will be available live on our website: www.

    2/26/26 6:45:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $APDN
    $AXDX
    $AXSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, President, and Secretary Patel Sujal M bought $65,238 worth of shares (25,000 units at $2.61), increasing direct ownership by 0.24% to 10,366,721 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/4/26 6:37:20 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by CFO and Treasurer Mowry Anna

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/4/26 5:31:36 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Chief Scientist Mallick Parag

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/4/26 5:31:31 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AGLE
    $APDN
    $AXDX
    $AXSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Axsome Therapeutics with a new price target

    Wolfe Research initiated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $230.00

    2/24/26 7:45:48 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Axsome Therapeutics from Overweight to Equal-Weight and set a new price target of $204.00

    1/8/26 8:36:26 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Summit Therapeutics from Underweight to Equal Weight and set a new price target of $18.00

    12/17/25 8:48:06 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $APDN
    $AXDX
    $AXSM
    SEC Filings

    View All

    Inotiv Inc. filed SEC Form 8-K: Other Events

    8-K - Inotiv, Inc. (0000720154) (Filer)

    3/10/26 8:13:31 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.

    SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

    3/4/26 7:33:36 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form S-8 filed by Nautilus Biotechnology Inc.

    S-8 - Nautilus Biotechnology, Inc. (0001808805) (Filer)

    2/26/26 4:27:31 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AGLE
    $APDN
    $AXDX
    $AXSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

    Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    8/19/22 12:36:14 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    5/11/22 10:51:07 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $APDN
    $AXDX
    $AXSM
    Leadership Updates

    Live Leadership Updates

    View All

    Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales

    SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering single-molecule proteome analysis, today announced the appointment of Amber Faust as Vice President of Sales. Ms. Faust joins Nautilus following the public debut of the Nautilus Voyager™ Platform, designed to deliver and scale Iterative Mapping, a method that enables single-molecule analysis of proteins and proteoforms across the proteome. Ms. Faust brings nearly two decades of commercial leadership experience in life sciences, with a focus on advancing adoption of emerging proteomics technologies across pharmaceutical, biotechnology, academic, clinical, and government sectors. S

    3/2/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

    Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellenceAppointment strengthens Phathom's leadership team and ability to execute its growth strategy in GI FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Sanjeev Narula as Chief Financial and Business Officer. "We welcome Sanjeev to Phathom's leadership team at this important stage of our growth," said Steve Basta, President

    10/6/25 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    $AGLE
    $APDN
    $AXDX
    $AXSM
    Financials

    Live finance-specific insights

    View All

    Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights Continued progress was made in processing and analyzing Tau proteoform samples from collaborators to support platform validation and expanding scientific publications. Externally generated Tau data measured on the Nautilus Voyager™ platform was presented at the World HUPO conference, and collaborators are advancing results toward submission for publication.Further progress was made

    2/26/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

    HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in

    2/23/26 4:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively,representing 65% and 66% year-over-year growth AUVELITY® 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively,representing 68% and 74% year-over-year growth SUNOSI® 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively,representing 40% and 32% year-over-year growth SYMBRAVO® 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively sNDA for AXS-05 for the treatment of Alzheimer's disease agitation granted Priority Review with PDUFAtarget action date of April 30, 2026 Acquired AXS-17, a novel

    2/23/26 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $APDN
    $AXDX
    $AXSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

    11/15/24 4:48:20 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

    11/15/24 4:20:24 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care